IL292639A - Heterocyclic nmda antagonists - Google Patents

Heterocyclic nmda antagonists

Info

Publication number
IL292639A
IL292639A IL292639A IL29263922A IL292639A IL 292639 A IL292639 A IL 292639A IL 292639 A IL292639 A IL 292639A IL 29263922 A IL29263922 A IL 29263922A IL 292639 A IL292639 A IL 292639A
Authority
IL
Israel
Prior art keywords
nmda antagonist
heterocyclic
heterocyclic nmda
antagonist
nmda
Prior art date
Application number
IL292639A
Other languages
English (en)
Hebrew (he)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of IL292639A publication Critical patent/IL292639A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL292639A 2019-11-14 2022-05-01 Heterocyclic nmda antagonists IL292639A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019206311A JP2021080177A (ja) 2019-11-14 2019-11-14 複素環化合物及びその用途
PCT/IB2020/000962 WO2021094832A1 (en) 2019-11-14 2020-11-12 Heterocyclic nmda antagonists

Publications (1)

Publication Number Publication Date
IL292639A true IL292639A (en) 2022-07-01

Family

ID=74141594

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292639A IL292639A (en) 2019-11-14 2022-05-01 Heterocyclic nmda antagonists

Country Status (21)

Country Link
US (3) US12630509B2 (cg-RX-API-DMAC10.html)
EP (1) EP4058430A1 (cg-RX-API-DMAC10.html)
JP (3) JP2021080177A (cg-RX-API-DMAC10.html)
KR (1) KR20220102629A (cg-RX-API-DMAC10.html)
CN (1) CN114728900A (cg-RX-API-DMAC10.html)
AR (1) AR120452A1 (cg-RX-API-DMAC10.html)
AU (1) AU2020385250B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022008367A2 (cg-RX-API-DMAC10.html)
CA (1) CA3158352A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022001241A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022008012A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220275A (cg-RX-API-DMAC10.html)
DO (1) DOP2022000099A (cg-RX-API-DMAC10.html)
EC (1) ECSP22037602A (cg-RX-API-DMAC10.html)
IL (1) IL292639A (cg-RX-API-DMAC10.html)
JO (1) JOP20220108A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022005778A (cg-RX-API-DMAC10.html)
PE (1) PE20221767A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022551173A1 (cg-RX-API-DMAC10.html)
TW (1) TWI908745B (cg-RX-API-DMAC10.html)
WO (1) WO2021094832A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
TWI873185B (zh) 2019-09-16 2025-02-21 日商武田藥品工業股份有限公司 唑稠合之嗒-3(2h)-酮衍生物
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) * 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途
WO2026060343A1 (en) 2024-09-16 2026-03-19 Neurocrine Biosciences, Inc. Solid forms comprising a nr2b nam antagonist

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492382A1 (fr) 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US5252563A (en) 1991-12-19 1993-10-12 G. D. Searle & Company 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrimidine compounds for treatment of neurotoxic injury
CA2191979A1 (en) 1994-06-20 1995-12-28 Muneo Takatani Condensed imidazole compounds, their production and use
JPH08319288A (ja) 1994-06-20 1996-12-03 Takeda Chem Ind Ltd 縮合イミダゾール誘導体、その製造法及び剤
JP3439551B2 (ja) 1994-11-08 2003-08-25 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US6387938B1 (en) 1996-07-05 2002-05-14 Mochida Pharmaceutical Co., Ltd. Benzimidazole derivatives
KR20000022398A (ko) 1996-07-05 2000-04-25 모치다 에이 신규 벤조이미다졸 유도체
EP1586584A1 (en) 1996-08-27 2005-10-19 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation comprising D-amino acids
JP2000159747A (ja) 1998-09-21 2000-06-13 Takeda Chem Ind Ltd 新規チオ―ル誘導体、その製造法および用途
US6420415B1 (en) 1998-09-21 2002-07-16 Takeda Chemical Industries, Ltd. Thiol compounds, their production and use
US6331640B1 (en) 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
EP1194449B1 (en) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
AU1153601A (en) 1999-10-29 2001-05-08 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole NMDA NR2B antagonists
US20020151534A1 (en) 2001-02-02 2002-10-17 Ries Uwe Joerg Antithrombotic compounds
DE10111842A1 (de) 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Antithrombotische Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
EP1390034A4 (en) 2001-04-03 2005-07-13 Merck & Co Inc N-SUBSTITUTED NONARYL HETEROCYCLO AMIDYL-NMDA / NR2B ANTAGONISTS
JPWO2003035641A1 (ja) 2001-10-22 2005-02-10 塩野義製薬株式会社 新規カルバモイルピロリドン誘導体
JP2004002405A (ja) 2002-04-26 2004-01-08 Takeda Chem Ind Ltd 新規チオール誘導体、その製造法および用途
CA2483515A1 (en) * 2002-04-26 2003-11-06 Takeda Pharmaceutical Company Limited Novel thiol derivative, method for producing the same and use thereof
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
JP2004161716A (ja) 2002-11-15 2004-06-10 Takeda Chem Ind Ltd Jnk阻害剤
CA2521907A1 (en) 2003-04-10 2004-10-21 Pfizer Inc. Bicyclic compounds as nr2b receptor antagonists
US20050137187A1 (en) 2003-12-23 2005-06-23 Souers Andrew J. Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
HUP0401523A3 (en) 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
JP5031745B2 (ja) 2005-08-12 2012-09-26 アストラゼネカ アクチボラグ 代謝型グルタミン酸受容体増強性イソインドロン
US20080234318A1 (en) 2005-08-31 2008-09-25 Kristjan Gudmundsson Chemical Compounds
AR057218A1 (es) 2005-12-15 2007-11-21 Astra Ab Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato
TWI403320B (zh) 2005-12-16 2013-08-01 Infinity Discovery Inc 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法
WO2007098352A2 (en) 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
WO2009004430A1 (en) * 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
AU2010210426B2 (en) 2009-02-06 2015-06-11 Imago Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
BR112012021806A2 (pt) 2010-03-01 2015-09-08 Myrexis Inc compostos e seus usos terapêusticos.
US8404859B2 (en) 2011-03-16 2013-03-26 Hoffmann-La Roche Inc. Thiazole and thiophene compounds
EP2694509B1 (en) 2011-04-05 2016-05-18 Pfizer Limited Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases
EP2721029B1 (en) 2011-06-16 2018-07-18 Merck Sharp & Dohme Corp. Imidazopyridin-2-one derivatives
FR2998892B1 (fr) 2012-12-04 2015-01-02 Pf Medicament Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
US20160031907A1 (en) 2013-03-15 2016-02-04 Epizyme, Inc. Substituted Benzene Compounds
CA2939639C (en) 2014-02-24 2023-01-24 Takeda Gmbh Uti fusion proteins
CN107074788B (zh) 2014-10-31 2019-09-20 厦门大学 取代杂环衍生物、其制备方法和用途
US10202376B2 (en) 2014-12-24 2019-02-12 Takeda Pharmaceutical Company Limited Heterocyclic compound
TWI636041B (zh) 2015-08-12 2018-09-21 美國禮來大藥廠 Cgrp受體拮抗劑
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Cgrp受體拮抗劑
WO2017033946A1 (ja) 2015-08-25 2017-03-02 武田薬品工業株式会社 複素環化合物
PL3439477T3 (pl) 2016-04-08 2020-11-16 Syngenta Participations Ag Mikrobiocydowe pochodne oksadiazolowe
EP3636281B1 (en) 2017-05-09 2023-11-01 Zhejiang University Method for treating depression, and pharmaceutical composition
US11230541B2 (en) 2017-07-28 2022-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3774800B1 (en) 2018-03-28 2024-11-13 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP6806735B2 (ja) 2018-05-30 2021-01-06 矢崎総業株式会社 車両用回路体および車両用回路体の製造方法
AU2019362061B2 (en) 2018-10-18 2024-09-26 Essa Pharma Inc Androgen receptor modulators and methods for their use
US12637418B2 (en) 2019-01-24 2026-05-26 Takeda Pharmaceutical Company Limited Heterocyclic compounds as antagonist of NMDA
WO2020198710A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2020196828A1 (ja) 2019-03-28 2020-10-01 武田薬品工業株式会社 含窒素複素環化合物
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途
JP2021080177A (ja) * 2019-11-14 2021-05-27 武田薬品工業株式会社 複素環化合物及びその用途

Also Published As

Publication number Publication date
KR20220102629A (ko) 2022-07-20
BR112022008367A2 (pt) 2022-10-18
JP2023502030A (ja) 2023-01-20
JP7726879B2 (ja) 2025-08-20
PH12022551173A1 (en) 2024-02-19
EP4058430A1 (en) 2022-09-21
CA3158352A1 (en) 2021-05-20
CN114728900A (zh) 2022-07-08
CL2022001241A1 (es) 2023-02-03
TW202132268A (zh) 2021-09-01
CO2022008012A2 (es) 2022-06-10
JP2021080177A (ja) 2021-05-27
PE20221767A1 (es) 2022-11-11
US20230134307A1 (en) 2023-05-04
US12630509B2 (en) 2026-05-19
CR20220275A (es) 2023-02-17
AU2020385250A1 (en) 2022-06-30
DOP2022000099A (es) 2022-08-31
JP2025159062A (ja) 2025-10-17
US11834409B2 (en) 2023-12-05
MX2022005778A (es) 2022-06-09
JOP20220108A1 (ar) 2023-01-30
AU2020385250B2 (en) 2026-08-13
AR120452A1 (es) 2022-02-16
US20230002318A1 (en) 2023-01-05
TWI908745B (zh) 2025-12-21
WO2021094832A1 (en) 2021-05-20
US11827601B2 (en) 2023-11-28
US20230150934A1 (en) 2023-05-18
ECSP22037602A (es) 2022-06-30
WO2021094832A8 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
IL292161A (en) New methylquinazolinone derivatives
IL283333A (en) New heterocyclic compounds
DK3810626T3 (da) Pcsk9-antagonistforbindelser
PT3958977T (pt) Derivados de camptotecina
EP3814381A4 (en) TRISPECIFIC ANTAGONISTS
EP4007756C0 (en) KIF18A INHIBITORS
LT3830085T (lt) Deuterinti lanifibranoro dariniai
PL4013751T3 (pl) Pochodne 2-hydroksycykloalkano-1-karbamoilu
EP3804707A4 (en) KINASE INHIBITOR
EP4077334C0 (en) FUROINDAZOLE DERIVATIVES
EP4021904C0 (en) ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES
DK3768669T3 (da) Piperazinazaspiroderivater
EP4073075A4 (en) Sstr5 antagonists
EP3992176A4 (en) EP2 ANTAGONIST
EP3884940A4 (en) Novel imidazole derivative
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
EP3991730A4 (en) NEUROKININ-1 ANTAGONIST
EP3942995A4 (en) SLIT LAMP MICROSCOPE
HUE065134T2 (hu) Vegyületek
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
DK3796975T3 (da) Sulfonylaminobenzamidderivater
DK3782986T3 (da) Heterocyklisk forbindelse
MA53886A (fr) Pantalon anti-accélération
EP3976797A4 (en) ANTI-CRISPR INHIBITORS
EP4317153A4 (en) Abhd6 antagonist